Research programme: anti-FGF8 monoclonal antibody - BioWa
Alternative Names: BIW-7034; BW-8406Latest Information Update: 01 Mar 2011
At a glance
- Originator Kyowa Hakko
- Developer BioWa
- Class Monoclonal antibodies
- Mechanism of Action Fibroblast growth factor inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Rheumatoid arthritis; Solid tumours
Highest Development Phases
- Discontinued Osteoarthritis; Prostate cancer; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 23 Oct 2008 Preclinical development is ongoing in USA
- 21 Oct 2005 Anti-FGF8 monoclonal antibody has been licensed to BioWa worldwide, except Asia
- 18 Aug 2005 This programme is still in active development for Cancer